Retinopathy of Prematurity (ROP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Retinopathy of Prematurity (ROP) Market Outlook

Thelansis’s “Retinopathy of Prematurity (ROP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, Competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, and market forecast under the potential Retinopathy of Prematurity treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Retinopathy of Prematurity (ROP) Overview

Retinopathy of prematurity (ROP) is an eye disease that affects some premature babies born before 31 weeks. A full-term pregnancy lasts between 38 -42 weeks. It is a condition that affects the retina, the tissue at the back of the eye. The retina detects light and sends signals to the brain, allowing you to see. Unwanted blood vessels grow on the baby's retina due to ROP. These blood vessels can later cause serious eye and vision problems. Sometimes, immediate treatment is required to avoid blindness. If not treated promptly, the child may suffer from severe permanent vision loss or even go blind. Most babies with ROP normally see for their age. Vision is only threatened when ROP progresses to the most severe stages. Fortunately, the majority of ROP resolves without causing vision loss. The most important factors in preventing ROP-related vision loss are effective screening and timely treatment (when indicated. Birth weight and gestational age are the most critical risk factors for developing severe ROP. Other factors associated with the presence of ROP include anemia, poor weight gain, blood transfusion, respiratory distress, breathing difficulties and the infant's overall health. There is active research into the correlation between levels of growth factors in the blood and ROP. Close monitoring has reduced the impact of oxygen use as a risk factor for developing ROP. Light levels do not affect the severity of ROP.

• The incidence of ROP is approximately 50% to 60% in preterm infants with a birth weight (BW) < 1500 g, while the rate of progression to severe ROP (Stages 3–5) has been reported to be approximately 15%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: